



CERTIFICATE OF ANALYSIS

Identity, purity and safety panel

Report No. UPL-2026-0186

Issued 2026-08-19

Page 1 of 1

SAMPLE

Compound **LL37**
Form Lyophilized powder
Label claim 5 mg / vial
Lot / batch LL-2338
Sample ID UPL-2026-0186
Vials received 5

CLIENT AND CHAIN OF CUSTODY

Client **USA Prime Peptides**
Client reference UPP-1381
Received 2026-08-14
Testing period 2026-08-17 to 2026-09-20
Storage 2-8 °C
Panel Full panel

TEST	METHOD	RESULT	SPECIFICATION	STATUS
Identity Chemistry	LC-MS	Conforms Observed [M+H] ⁺ consistent with theoretical	Matches reference	PASS
Purity Chemistry	HPLC-UV	99.6%	Report value	PASS
Net content Chemistry	Gravimetric	4.99 mg 99.7% of label claim	90 - 110 % of label claim	PASS
Water content Chemistry	Karl Fischer	6.88%	<= 10.0 %	PASS
Residual solvents Safety	GC-MS	Pass Acetonitrile 136 ppm; DMF not detected	Within ICH Q3C limits	PASS
Endotoxin Safety	LAL kinetic	0.19 EU/mg Spike recovery 93%	<= 1.0 EU/mg	PASS
Heavy metals Safety	ICP-MS	Pass As 0.052 · Cd 0.003 · Pb 0.046 · Hg 0.043 ug/g	As 1.5, Cd 0.2, Pb 0.5, Hg 0.3 ug/g	PASS
Bioburden Safety	USP <61>	TAMC <10 CFU/g TYMC <10 CFU/g	TAMC <= 100, TYMC <= 10 CFU/g	PASS
Sterility Safety	USP <71>	No growth	No growth	PASS

OVERALL: PASS All tests meet specification

99.6%

Jane Rivera

Analyst
Jane Rivera, Senior Analyst
Signed Aug 21, 2026

Dr. Mark Chen, MD

QA Reviewer
Mark Chen, QA Director
Approved Aug 21, 2026



Verify this certificate
Report UPL-2026-0186